Brad Somer
Overview
Explore the profile of Brad Somer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
441
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hurwitz H, Tan B, Reeves J, Xiong H, Somer B, Lenz H, et al.
Oncologist
. 2018 Dec;
24(7):921-932.
PMID: 30552157
Background: First-line treatment for metastatic colorectal cancer (mCRC) typically entails a biologic such as bevacizumab (BEV) with 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX) or 5-fluorouracil/leucovorin/irinotecan (FOLFIRI). STEAM (NCT01765582) assessed the efficacy of BEV plus...
2.
Motzer R, Jonasch E, Agarwal N, Bhayani S, Bro W, Chang S, et al.
J Natl Compr Canc Netw
. 2017 Jun;
15(6):804-834.
PMID: 28596261
The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non-clear cell renal carcinoma. These guidelines are developed by a multidisciplinary...
3.
Motzer R, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger G, et al.
J Natl Compr Canc Netw
. 2015 Jun;
13(6):772-99.
PMID: 26085393
Germ cell tumors (GCTs) account for 95% of testicular cancers. Testicular GCTs constitute the most common solid tumor in men between the ages of 20 and 34 years, and the...
4.
Motzer R, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger G, et al.
J Natl Compr Canc Netw
. 2015 Feb;
13(2):151-9.
PMID: 25691606
The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non-clear cell renal carcinoma. These NCCN Guidelines Insights highlight the recent...
5.
Motzer R, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger G, et al.
J Natl Compr Canc Netw
. 2014 Mar;
12(2):175-82.
PMID: 24586079
These NCCN Guidelines Insights highlight treatment recommendations and updates specific to the management of patients with advanced non-clear cell carcinoma included in the 2014 version of the NCCN Clinical Practice...
6.
Cho D, Hutson T, Samlowski W, Sportelli P, Somer B, Richards P, et al.
Cancer
. 2012 Jun;
118(24):6055-62.
PMID: 22674198
Background: The clinical activity of allosteric inhibitors of mammalian target of rapamycin (mTOR) inhibitors in renal cell carcinoma (RCC) may be limited by upstream activation of phosphatidylinositol 3 (PI3)-kinase/Akt resulting...